Biologics CDMO Market Report 2026

The biologics cdmo market size has grown rapidly in recent years. It will grow from $24.15 billion in 2025 to $27.56 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to rise in biologics research, advancements in cell culture technologies, increasing prevalence of chronic diseases, growth of biosimilar pipelines, government support for biopharma manufacturing.

The biologics cdmo market size is expected to see rapid growth in the next few years. It will grow to $48.07 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to surge in gene and cell therapy development, adoption of automation and robotics in CDMO processes, expansion of global biologics manufacturing capacity, increasing investment in precision medicine, rising demand for cost-effective biologics. Major trends in the forecast period include expansion of biologics cdmo services, growth in mammalian cell-based production, increase in outsourcing of gene therapy manufacturing, adoption of advanced bioprocessing techniques, rising demand for biosimilars.

The surge in demand for cell and gene therapy is expected to drive the growth of the biologic CDMO market going forward. Cell and gene therapies are innovative medical approaches that use living cells or genetic material to target the underlying causes of disease at the cellular or genetic level, offering potential treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The demand for these therapies is increasing due to their ability to provide novel treatments by addressing the root genetic or cellular causes of diseases. Biologic CDMOs offer expertise in handling living cells, viral vectors, and genetic material, enabling the safe and efficient production of cell and gene therapies while helping biopharmaceutical companies navigate regulatory requirements and technical challenges, thereby facilitating the transition from research to clinical application. For instance, in March 2024, according to IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies rose to $5.9 billion in 2023, representing a 38% increase from 2022. Therefore, the surge in demand for cell and gene therapy is driving the growth of the biologic CDMO market.

Major companies in the biologics CDMO market are focusing on developing technologically advanced solutions, such as novel cell lines, to enhance biopharmaceutical development and manufacturing efficiency. This technology enables the production of therapeutic antibodies with improved potency, addressing challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturer specializing in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines, designed to produce antibodies that are 100% fucose-free and exhibit increased potency without compromising other performance attributes. These stable, scalable, and productive cell lines support therapeutic development from discovery-stage research through commercial manufacturing, overcoming key immunotherapy R&D challenges.

In December 2024, Novo Holdings A/S, a Denmark-based investment company, completed the acquisition of Catalent, Inc., for an undisclosed amount. Through this acquisition, Novo Holdings aims to expand its portfolio in the contract development and manufacturing organization (CDMO) sector, enhance global manufacturing capabilities, and support the growth of innovative drug development solutions. Catalent, Inc. is a US-based CDMO that provides advanced delivery technologies, development, and manufacturing services for drugs, biologics, and consumer health products.

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics.

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the biologics CDMO market by increasing the cost of importing raw materials, lab equipment, and specialized cell culture media, which has put pressure on operational expenses. The mammalian cell and biosimilar production segments, particularly in Asia-Pacific and North America, are most impacted due to their reliance on global supply chains. While these tariffs pose challenges, they have also encouraged local sourcing, investment in domestic manufacturing capabilities, and accelerated adoption of innovative, cost-efficient biologics production technologies.

The biologics cdmo market research report is one of a series of new reports that provides biologics cdmo market statistics, including biologics cdmo industry global market size, regional shares, competitors with a biologics cdmo market share, detailed biologics cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the biologics cdmo industry. This biologics cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A biologics contract development and manufacturing organization (CDMO) is a service provider that assists pharmaceutical companies in the development and production of biologic drugs, including vaccines, blood and blood components, allergens, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins.

The main cell types used in biologics CDMOs are mammalian and non-mammalian. Mammalian cells are derived from mammals and are commonly used in the production of biologics and cell-based therapies due to their ability to produce complex proteins and maintain post-translational modifications. The product types include biologics and biosimilars.

The biologics CDMO market consist of revenues earned by entities by providing services such as process development, analytical development, cell line development, supply chain management, and fill-finish services. The biologics CDMO market also includes sales of monoclonal antibodies, recombinant proteins, antisense and molecular therapy, and vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.